Burden of Cardiovascular Diseases in China, 1990-2016: Findings From the 2016 Global Burden of Disease Study.
Shiwei Liu, Yichong Li, Xinying Zeng...
https://pubmed.ncbi.nlm.nih.gov/30865215Actively Recruiting
Age: 18Years +
All Genders
ID06216847
Clinical Outcomes of Patients With Coronary Artery Disease Cohort Study
Led by Shenyang Northern Hospital · Updated on 2025-09-10
10000
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Coronary heart disease (CHD) is a leading cause of death worldwide, with complex causes that make standard prevention methods less effective. This research is a prospective, multi-center cohort study involving patients hospitalized with confirmed or suspected CHD. It aims to create a comprehensive dataset for better diagnosis and treatment of CHD and to study how key treatment strategies affect patient outcomes in real-world settings, helping to improve care pathways. The study includes patients who have been hospitalized for CHD and meet specific diagnostic criteria, including previous procedures or tests indicating coronary artery issues. Participants will have undergone various coronary imaging and functional tests such as coronary CT angiography, intravascular ultrasound, optical coherence tomography, and flow reserve measurements. The study will collect detailed clinical data over time to track disease progression and treatment impacts. Participants will be followed regularly to assess outcomes such as ischemic events within 12 months, and major cardiovascular events, cardiac death, stent thrombosis, and bleeding events over 1 to 5 years. Data will be gathered through clinical evaluations, imaging, laboratory tests, and follow-up visits to monitor health status and treatment effects. This long-term follow-up aims to provide insights into personalized risk assessment and treatment optimization for CHD patients.
CONDITIONS
Brief Title
Clinical Outcomes of Patients With Coronary Artery Disease
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Hospitalized due to confirmed or suspected coronary heart disease with one of the following: previous PCI or CABG; previous myocardial infarction; coronary angiography showing 50% stenosis in major coronary vessels; chest pain with pre-test CHD probability > 65%; laboratory evidence of myocardial ischemia; coronary CT angiography showing 30% stenosis in major coronary vessels
- Undergoing at least one coronary imaging test (CTA, IVUS, or OCT) and one functional examination (FFR, CT-FFR, or QFR)
- Provided written informed consent
You will not qualify if you...
- History of mental illness, drug or alcohol abuse, or inability to cooperate with follow-up visits
- Life expectancy less than 1 year
- Pregnant or planning pregnancy within 1 year
- Participation in any other clinical trial
- Other conditions considered unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Up to 1 month
Participants undergo coronary imaging tests and functional examinations to assess coronary heart disease status.
1 to 2 visits depending on tests required
Long-term Monitoring
Duration - Up to 5 years
Participants are observed over multiple years to track clinical outcomes and cardiovascular events related to coronary heart disease.
Annual visits for up to 5 years
Trial Site Locations
Total: 1 location
1
General Hospital of Northern Theater Command
Shenyang, Liaoning, China, 110016
Actively Recruiting
Loading map...
Research Team
Y
Yi Li, MD
Y
Yaling Han, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Report on Cardiovascular Health and Diseases in China 2021: An Updated Summary.
writing committee of the report on cardiovascular health and diseases in china
https://pubmed.ncbi.nlm.nih.gov/35945174Precision Medicine and Personalized Medicine in Cardiovascular Disease.
Gemma Currie, Christian Delles
https://pubmed.ncbi.nlm.nih.gov/30051409Inflammation, Aging, and Cardiovascular Disease: JACC Review Topic of the Week.
Luca Liberale, Lina Badimon, Fabrizio Montecucco...
https://pubmed.ncbi.nlm.nih.gov/35210039Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease.
Christopher S Marnell, Alexander Bick, Pradeep Natarajan
https://pubmed.ncbi.nlm.nih.gov/34298011Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Paul M Ridker, Brendan M Everett, Tom Thuren...
https://pubmed.ncbi.nlm.nih.gov/28845751Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
Jean-Claude Tardif, Simon Kouz, David D Waters...
https://pubmed.ncbi.nlm.nih.gov/31733140Colchicine in Patients with Chronic Coronary Disease.
Stefan M Nidorf, Aernoud T L Fiolet, Arend Mosterd...
https://pubmed.ncbi.nlm.nih.gov/32865380Fractional flow reserve versus angiography for guiding percutaneous coronary intervention.
Pim A L Tonino, Bernard De Bruyne, Nico H J Pijls...
https://pubmed.ncbi.nlm.nih.gov/19144937Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial.
Bo Xu, Shengxian Tu, Lei Song...
https://pubmed.ncbi.nlm.nih.gov/34742368